Mini Review: Heparin treatment in COVID-19: Where are we?

M. Rizzo, I. Pezone, M. Amicone, E. Riccio, A. Pisani
{"title":"Mini Review: Heparin treatment in COVID-19: Where are we?","authors":"M. Rizzo, I. Pezone, M. Amicone, E. Riccio, A. Pisani","doi":"10.35841/2249-622X.72.19503","DOIUrl":null,"url":null,"abstract":"Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome with a high mortality rate; it is caused by SARS-CoV-2, a new virus of the Coronaviridae family that emerged in Wuhan, Hubei, China, in December 2019 and rapidly spread worldwide until declared by the World Health Organization a global pandemic on March 11th, 2020. The race for an effective drug to prevent or treat SARS-CoV-2 infection is the highest priority among health care providers, government officials, and the pharmaceutical industry. Despite scientific effort, no pharmacological intervention has proven definitively beneficial, and care is primarily supportive.","PeriodicalId":8517,"journal":{"name":"Asian Journal of Biomedical and Pharmaceutical Sciences","volume":"76 1","pages":"1-3"},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Biomedical and Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35841/2249-622X.72.19503","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome with a high mortality rate; it is caused by SARS-CoV-2, a new virus of the Coronaviridae family that emerged in Wuhan, Hubei, China, in December 2019 and rapidly spread worldwide until declared by the World Health Organization a global pandemic on March 11th, 2020. The race for an effective drug to prevent or treat SARS-CoV-2 infection is the highest priority among health care providers, government officials, and the pharmaceutical industry. Despite scientific effort, no pharmacological intervention has proven definitively beneficial, and care is primarily supportive.
迷你综述:肝素治疗COVID-19:我们在哪里?
2019冠状病毒病(COVID-19)是一种死亡率很高的严重急性呼吸系统综合征;它是由SARS-CoV-2引起的,SARS-CoV-2是一种新型冠状病毒科病毒,于2019年12月在中国湖北武汉出现,并在全球迅速传播,直到2020年3月11日世界卫生组织宣布全球大流行。研发一种有效的药物来预防或治疗SARS-CoV-2感染是医疗服务提供者、政府官员和制药行业的首要任务。尽管科学努力,没有药理干预被证明是绝对有益的,护理主要是支持性的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信